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Abstract: Chitosan scaffolds, combined with bioactive glass 46S6, were prepared to serve as 
gentamicin sulfate delivery in situ systems for bone biomaterials. This work presents a study 
about the effect of the ratio chitosan/ bioactive glass (CH/BG) on the release of gentamicin 
sulfate and on the bioactivity during in vitro experiments.  
SEM observations allowed understanding the bond between the glass grains and the chitosan 
matrix. In vitro results showed that scaffolds form a hydroxyapatite (HA) Ca10(PO4)6(OH)2  after 
15 days of immersion in a simulated body fluid (SBF). 
The interest of this study is to see that the increase of the content of bioactive glass in the 
chitosan matrix slows the release of gentamicin sulfate in the liquid medium. Starting 
concentration of gentamicin sulfate has an influence on the relaxation time of the scaffolds. 
Indeed, an increasing concentration delays the return to a new equilibrium. Contents of chitosan 
and bioactive glass do not affect the relaxation time. Synthesized scaffolds could be adapted to a 
clinical situation: severity and type of infection, weight and age of the patient. 
Keywords: Scaffolds, Drug delivery system, Relaxation time, Chitosan, Gentamicin sulfate.  
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1. Introduction 
Bone loss or failure resulting from a disease or an accident is an important problem in the health 
field. In the maxillofacial and orthopedic surgery, metal prosthesis, ceramics and other synthetic 
biomaterials are widely used to bone repair. Nowadays, tissue engineering promises alternative 
approaches to repair the loss or malfunction of a tissue or an organ [1]. Indeed, a lot of porous 
scaffolds synthesized with different biodegradable polymers have been fabricated and used for 
tissue engineering of liver [2], nerve [3] and bone [4]. Natural polymers already have been 
studied using lyophilization method [5]: alginate [6], collagen and other synthetic polymers as 
polyvinyl alcohol [7]. Chitosan (figure 1) presents important biological characteristics as 
biocompatibility, biodegradability, non-toxicity, affinity to proteins, antibacterial, antitumoral 
properties [8-10]. It used for a lot of medical applications as sutures, bone substitutes and drug 
delivery [11]. In contrast to all other biodegradable polymers, chitosan is the only one exhibiting 
a cationic character rendering it unique among all others. The cationic character being based on 
its primary amino groups is responsible for various properties and subsequently for its use in 
drug delivery systems [12]. Studied scaffolds were reinforced by the bioactive glass 46S6. This 
glass can create a hydroxyapatite layer on its surface when it is immersed in SBF [13-14] and 
allow creating an intimate bond with the bone tissue. In a previous study, the comparison of the 
behavior of pure glass and composite glass chitosan highlighted the effects of chitosan on the 
kinetic of chemical reactivity and bioactivity. The advantages of the novel structure of hybrid 
biomaterial 46S6-chitosan lead to the acceleration of the two parameters compared to pure glass 
46S6 [14]. Gentamicin-sulfate (figure 2) was combined with these hybrid biomaterials because it 
is active against Staphylococcus aureus responsible for osteomyelitis [15-16]. Gentamicin sulfate 
belong aminoglycoside class of bactericidal antibiotic [17]. The use of antibiotic delivery 
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systems for treatment of bone infection is a subject in full development. The poor circulation of 
blood in the osseous tissue makes necessary the supply of great amount of antibiotics to reach the 
adequate therapeutic level in the affected region. These systems allow the release by diffusion of 
an antibiotic through a biodegradable polymer matrix [18-21]. Some studies showed that 
different stimuli as temperature or pH [18] involve the release of the drug [22-25]. The present 
study gives special attentions to:  
i) The synthesis of chitosan/bioactive glass/gentamicin sulfate scaffolds and their physico-
chemical characterizations;  
ii) The modifications on the surface of scaffolds after immersion in SBF and the controlled 
release of gentamicin sulfate evaluated by UV-spectrophotometry. 
iii) The elaboration of mathematic models and the interpretation of the time of relaxation 
concerning the release of gentamicin sulfate. 
2. Materials and methods  
2.1. Preparation of scaffolds 
The synthesis of scaffolds is divided in three main steps (figure 3).  
First, the bioactive glass 46S6 was prepared from sodium metasilicate (Na2SiO3), silicon oxide 
(SiO2), calcium metasilicate (CaSiO3) and sodium metaphosphate (Na3P3O9). It is composed of 
46% of SiO2, 24% of CaO, 24% of Na2O and 6% of P2O5. It was synthesized by the melting 
process as described in a previous work [26]. Obtained glasses were grinded and sift to obtain a 
fine granulometry less than 40 m. The second step has consisted to dissolve 3 g of chitosan 
powder, with a medium molecular weight, in acetic acid solution 1% v/v. The solution was 
stirred under magnetic stirring at room temperature during 24 hours in order to dissolve all the 
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chitosan powder. The final step is the preparation of three scaffolds: 2CH-1BG, 1CH-1BG and 
1CH-2BG presenting different ratios chitosan/glass (CH/BG) (table 1). The glass was added in 
the chitosan solution. The mixtures were homogenized for 24 hours in an ultrasonic bath. To 
elaborate scaffolds with gentamicin sulfate, the antibiotic was added in the mixtures. In this 
work, scaffolds were synthesized with 1% w/v and 3% w/v of gentamicin sulfate.  These 
concentrations have been chosen to avoid reaching the threshold of toxicity of gentamicin 
sulfate. Indeed, it can be highly nephrotoxic, particularly if multiple doses accumulate during 
treatment.  
Once the homogenization of chitosan/bioactive glass/gentamicin sulfate completed, the solutions 
were cast into well-plates. They were frozen at -20°C for all-night to frozen the core of the 
material and placed in a freeze-dryer at 0.65 mbar at -60°C during 24 hours to remove all 
solvents in samples. Obtained scaffolds were washed in a NaOH solution 0.4% w/v and distilled 
water to eliminate traces of acetic acid. They were frozen and lyophilized as previously stated. 
Finally, scaffolds of 13 mm of diameter were obtained with different amounts of chitosan and 
bioactive glass.  
2.2. In vitro evaluation of the bioactivity  
In vitro assays, as described in a previous work [14], were realized in a SBF whose the chemical 
composition is similar to the blood plasma (table 2) [14, 27].  
30 mg of powder samples were immersed during 1, 2, 7, 15 and 30 days in triplicate in 60 mL of 
SBF and maintained under controlled stirring at 50 rpm. At the end of soaking time, the powder 
samples removed and rinsed with deionized water to stop the exchange reactions. The powder 
samples dried and stored for further investigation of the formation of HA layer on the surface of 
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powder samples. This was verified by fourier transform infrared spectroscopy (FTIR, Bruker 
equinox 55 spectrophotometer) and X-ray diffraction (XRD, Bruker AXS D8 Advance 
diffractometer). The SBF solutions were stored in fridge to evaluate the ionic exchanges between 
materials and SBF by ICP-OES (Spectro Ciros Vision Ametek).  
2.3. In vitro study of the release of gentamicin sulfate
The controlled release of gentamicin sulfate was studied after immersion of scaffolds of 300 mg 
(±5 mg) in 10 mL of a physiological saline solution (BioWhittaker
® 
Dulbecco's PBS) without 
calcium and magnesium to avoid the chemical reaction of bioactivity. Its buffering capacity is 
based on the dihydrogen/hydrogen pair which is also one of three major mechanisms for 
maintaining blood pH:  
HPO4
2-
+ H
+
 = H2PO4
-
The release of gentamicin sulfate was studied after 5, 10, 20, 30 minutes and 1, 2, 6 hours in 
triplicate. These notices were chosen because some studies have proved that gentamicin sulfate is 
released quickly [18-28]. PBS solutions were analyzed at 256 nm using UV spectrophotometer 
(Jenway 6705) to measure the concentration of gentamicin sulfate. The blank control is 10 mL of 
PBS without materials and the calibration curve was plotted using standards solutions of 
increasing concentrations of gentamicin sulfate from 1 to 30 mg.mL
-1
. The results were averaged 
with standard deviation.  
3. Results and discussions  
3.1. Surface characterizations of scaffolds
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Porosity is an important characteristic for biomaterials because it supports the cells colonization, 
the deposit of organic matter and the transport of drugs or molecules for therapeutic uses. It was 
evaluated by Brunauer-Emmet-Teller (BET) method using Micromeritics ASAP 2010 analyzer. 
According to the International Union of Pure and Applied Chemistry (IUPAC) classification, the 
obtained isotherms (figure 4) belong to type H3. The curves of adsorption and desorption form a 
hysteresis loop. The hysteresis cycle is due to the capillary condensation phenomenon 
characteristic of a mesoporous material (pore diameter between 2 nm and less than 50 nm). On 
each hysteresis cycle, shoulders, characteristic of several families of mesopores, are observed at 
P/P0 = 0.5. According to the BET and Barrett-Joyner-Halenda (BJH) methods, the values of 
specific surface area pore size and pore volume (table 3) were calculated. An increase of specific 
surface area is observed when the ration CH/BG increases: 6.90 (± 0.07) m².g
-1
 for 1CH-2BG 
scaffolds, 7.60 (± 0.08) m².g
-1
 for 1CH-1BG and 7.90 (± 0.08) m².g
-1
 for 2CH-1BG. The same 
observations for pore volume were registered: 7.00 (± 0.07) mm
3
.g
-1
 for 1CH-2BG scaffolds, 
7.40 (± 0.07) mm
3
.g
-1 
for 1CH-1BG scaffolds and 2CH-1BG scaffolds present 8.10 (± 0.08) 
mm
3
.g
-1
 of pore volume. It was found that the specific surface area and pore volume increase 
when the introduced content of chitosan increases [14]. Moreover, specific surface area of 46S6 
and chitosan are respectively 0.9 and 0.7 m².g
-1 
[14]. The association of chitosan with the 
bioactive glass 46S6 increases the specific surface area. Furthermore, with a high content of 
chitosan, the average pore diameter also increases. Indeed, 2CH-1BG scaffolds present an 
average pore diameter of 5.2 nm, 1CH-1BG 3.6 nm and 1CH-2BG 4.0 nm.  
SEM observations were performed using a Jeol JSM 6301F scanning electron microscope. The 
surfaces of scaffolds before immersion in the SBF were registered. For all scaffolds, pores are 
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visible (figures 5.a to 5.c). Bioactive glass particles seem to be pasted on the chitosan matrix for 
each type of scaffolds (figures 5.d to 5.f). All scaffolds have smooth chitosan matrix which coats 
the larger glass grains. Concerning the porosity:  
-2CH-1BG scaffolds possess a wide variety of pores (fine and ample pores), that explains why 
they have a pore volume and an average pore diameter larger than the other two.  
-1CH-1BG scaffolds present the same morphology of pores compared to 2CH-1BG scaffolds but 
they have a less homogeneous surface.  
-1CH-2BG scaffolds have a more homogeneous surface but they present wider pores, this could 
explain an average pore diameter greater than 1CH-1BG scaffolds but a smaller pore volume.  
These observations clearly confirm the obtained results by adsorption of N2. These variations of 
porosity function of the ration CH/BG could expand the capacity of uses of these biomaterials 
for medical applications. 
3.2. Characterizations of scaffolds after in vitro assays
The XRD patterns of 1CH-1BG, 1CH-2BG, and 2CH-1BG scaffolds after 30 days of immersion 
in the SBF are presented in figure 6. Several references as 46S6, chitosan scaffolds before 
immersion were chosen to observe an eventual change in the structure [27-32]. The 
hydroxyapatite was chosen as reference to present its eventual formation on materials. A halo of 
diffraction is observed for 2CH-1BG scaffolds between 15 and 25 (2°) due to the high amount 
of chitosan. After 30 days of immersion in the SBF, the formation of hydroxyapatite is 
confirmed by the appearance of two peaks of diffraction: at 25.9 (2°) corresponding to the (002) 
apatite reflection and 31.8 (2°) corresponding to the (211) apatite reflection [33]. For all the 
scaffolds, the bioactivity is observed from 15 days of immersion. Therefore, the content of 46S6 
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does not have a significant effect on the bioactivity of scaffolds. Indeed, the hydroxyapatite 
appears for each scaffold. The bioactive glass releases calcium, phosphorus and silicon ions in 
the SBF and allows the formation of hydroxyapatite. The ionic exchanges study was performed 
by using ICP-OES. However, a better crystallization of hydroxyapatite is observed for 2CH-
1BG. This phenomenon may be related to the specific surface area of the samples. Having a 
larger specific surface area and a larger pore volume, 2CH-1BG scaffolds promotes the flow of 
the SBF through the material, favoring ion exchanges and forming a better crystallized 
hydroxyapatite.  
In order to observe eventual structural modifications of our scaffolds after soaking in SBF 
solution, the FTIR spectra after 30 days of immersion are presented in figure 7. Characteristics 
bands are resumed in table 4.  
The disappearance of the band at 807 cm
-1
 characteristic of the symmetric Si-O-Si stretching 
bond is observed. For all the scaffolds, after 30 days of immersion, the formation of 
hydroxyapatite is confirmed by the bands corresponding to the P-O chemical bond at 563, 605 
cm
-1 
[34] and two slight shoulders at 958 and 1105 cm
-1 
are observed. At 1655 cm
-1
, a band 
characteristic of (Amide I: C=O) function appears at the expense of the disappearance of the 
band at 1568 cm
-1
. Furthermore, the bands corresponding to (Amide :  N-H) chemical bond at 
645 and 620 cm
-1
 disappear, ditto to the band at 522 cm
-1
 characteristic of the symmetric Si-O-Si 
stretching bond.  
The bands characteristics of P-O bonds of hydroxyapatite for 2CH-1BG scaffolds are more 
intense and are characteristics of a better crystallization. This confirms the hypothesis of the 
results obtained by XRD.  
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These results confirm the bioactive character of scaffolds. ICP-OES analyses were performed to 
measure the ionic exchanges between scaffolds and SBF and to understand the mechanism of 
bioactivity.  
After immersion in the SBF solution, SEM micrographs (figure 8) do not reveal the layer of 
hydroxyapatite. However, modifications of surfaces are observed. They present a creamy aspect 
after immersion. The glass grains, present on the surface, have disappeared. The coated glass 
grains are more visible because the chitosan matrix is torn by location. The hydroxyapatite, 
detected by XRD and FTIR, is not observed. It may be that it has formed inside the material 
under the chitosan matrix.   
The chemical elements Si, Ca and P have been carefully selected for quantitative analyses by 
ICP-OES. This physical method presents a high sensitivity and allows having the kinetic of 
bioactivity.  Indeed, silicon is an indicator of the dissolution of bioactive glass while calcium and 
phosphorus help to understand the formation of calcium phosphate [35-36]. These chemical 
elements were measured in the SBF solution at different periods (2, 4, 8 and 16 hours and 1, 2, 7, 
15 and 30 days).  
Silicon (figure 9.a) is released quickly during the first hours going from 0 to 19 ppm on average. 
It is released up to 30 days. The 1CH-2BG scaffolds, containing more bioactive glass, release 
much silicon in the SBF (up to 26 ppm). 1CH-1BG and 2CH-1BG scaffolds release respectively 
19.5 and 14 ppm after 30 days of immersion. Indeed, the bioactive glass grains are locked in the 
chitosan matrix which explains the lower release. These results also prove that the silica network 
of the 46S6 is progressively degraded in the SBF solution.   
For calcium (figure 9.b) and phosphorus (figure 9.c) releases, the same looks are distinguished 
for scaffolds. Indeed, from 2 hours up to 30 days, calcium and phosphorus concentrations 
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decrease continually. It means that there is a consumption of calcium and phosphorus by 
scaffolds. However, more the content of bioactive glass in scaffolds is high and more calcium 
and phosphorus are consumed. In contrast, more the amount of chitosan is important, more 
calcium and phosphorus are consumed slowly. The slower kinetics of absorption of calcium and 
phosphorus for 2CH-1BG scaffolds could explain the better crystallization observed by XRD and 
FTIR. Indeed, crystallization is a function of time. It is possible that this low kinetics of 
absorption of calcium and phosphorus suitable for better crystallization of hydroxyapatite. 
Moreover, this slowdown of absorption can be explained by the coating of glass grains by the 
chitosan matrix. Indeed, the chitosan is introduced in a high amount for 2CH-1BG scaffolds and 
glass grains trapped in the chitosan absorb more hardly the necessary chemical elements for the 
formation of hydroxyapatite. However, the integration of bioactive glass with its high bioactivity 
[35-36] promotes the consumption of calcium and phosphorus to create crystals of 
hydroxyapatite. Therefore, it explains the formation of hydroxyapatite in materials from 15 days 
and the ionic exchanges for each scaffold.  
All these results emphasize the phenomena of bioactivity of scaffolds. XRD and FTIR 
spectroscopy reveal the appearance of a hydroxyapatite for each scaffold. ICP-OES gives the 
ionic exchanges during this phenomenon. Silicon ions are released; calcium and phosphorus ions 
are consumed by scaffolds according to the content of chitosan and bioactive glass up to 30 days 
of immersion explaining the formation of hydroxyapatite. This hydroxyapatite is more or less 
well crystallized according to the chemical composition. With their different kinetic of 
bioactivity, these materials may be suitable for various medical applications.  
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The originality of these materials is that they can be elaborated with a drug in order to treat 
locally an infection. Scaffolds have been charged with gentamicin sulfate and the study of the 
release of this drug was undertaken.  
3.3. Kinetic of the controlled release of gentamicin sulfate
Local antibiotic therapy has been already used in all types of bone infections. The aim of this 
investigation was to study the effect of the content of chitosan and bioactive glass on the kinetic 
of release of gentamicin sulfate.  
The curves of release of gentamicin sulfate present same appearance (figure 10.a and 10.b): 
Mathematical relations (table 5 and 6), corresponding to the liberation of drug in the PBS 
solution versus time of immersion, were established. In this relation, the relaxation time 
parameter () characteristic of scaffolds was deducted.  is related to the response of the system 
studied (scaffold) to an instantaneous disturbance (immersion in PBS).  represents the order of 
magnitude of time at which the new equilibrium is reached (limit concentration C0). 
The release of gentamicin sulfate, in the PBS solution, follows a law of the type: 








	




−−×=
τ
t
CgC exp10
Where:  
Cg is the gentamicin sulfate concentration, C0 is the gentamicin sulfate limit concentration, t the 
immersion time and  the relaxation time of the system.  
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Scaffolds, with 1% of gentamicin sulfate, need to 29 minutes to reach their new equilibrium 
versus 38 minutes for scaffolds with 3% of gentamicin sulfate. 
For scaffolds doped with 1% of gentamicin sulfate (figure 10.a), the release is fast up to 60 
minutes of immersion. The gentamicin sulfate concentration goes from 0 to: 5.6 mg.mL
-1
 for 
2CH-1BG, 3.7 mg.mL
-1
 for 1CH-1BG and 1.7 mg.mL
-1
 for 1CH-2BG. A stability of release is 
observed after 60 minutes. At 360 minutes, the concentration of gentamicin sulfate reaches 5.9 
mg.mL
-1
, 4.0 mg.mL
-1
 and 1.9 mg.mL
-1
 for respectively 2CH-1BG, 1CH-1BG and 1CH-2BG.  
Concerning scaffolds doped with 3% of gentamicin sulfate (figure 10.b), the release also is fast 
up to 120 minutes. The concentration of gentamicin sulfate goes from 0 to: 11.9 mg.mL
-1
 for 
2CH-1BG, 5.6 mg.mL
-1
 for 1CH-1BG and 1CH-2BG scaffolds. After 120 minutes, a stability of 
release is observed and the concentration of gentamicin sulfate reaches 12.3 mg.mL
-1 
for 2CH-
1BG, 6.5 mg.mL
-1
 for 1CH-1BG and 1CH-2BG scaffolds. 
A difference of a factor 2 is observed between the data of concentration of gentamicin sulfate for 
scaffolds with 1% of gentamicin sulfate and them with 3% of gentamicin sulfate. Several 
characteristics of scaffolds can explain the delivery of gentamicin sulfate such as their porosity 
and their specific area [13]. Indeed, 2CH-1BG scaffolds, having a larger specific surface area 
(7.9 m².g
-1
) and a larger pore volume (8.1 mm
3
.g
-1 
), release more gentamicin sulfate (with either 
1 or 3%) than the two other types of scaffolds; followed by 1CH-1BG scaffolds and 1CH-2BG 
scaffolds. It has also been reported in several studies that the nature of the antibiotic were 
involved in the kinetics of release [13]. Indeed, the gentamicin sulfate presents an early release 
due to its hydrophilic character [13].  
For all scaffolds, the variations of the content of bioactive glass and that of chitosan do not 
impact the relaxation time. In contrast, the concentration of gentamicin sulfate increases the 
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relaxation time. The limit concentration depends on the content of bioactive glass and chitosan. 
The presence of a high content of chitosan increases the limit concentration C0. 
These results are interesting because for scaffolds doped with 1% or 3% of gentamicin sulfate, 
different behaviors are observed. Indeed, 2CH-1BG has a better kinetic of release that 1CH-1BG 
and 1CH-2BG. The pore volume and surface area, due to the introduction of different contents of 
chitosan and bioactive glass may explain this phenomenon. The scaffolds doped with 1% 
gentamicin sulfate have a stable release from 1 hour of immersion while for scaffolds doped with 
3% gentamicin sulfate; stabilization is observed from 2 hours of immersion in PBS. Moreover, 
the introduction of a high concentration of drug causes a later stabilization and also more 
important release of drug. The hydrophilic character of chitosan and gentamicin sulfate may 
explain the high release of gentamicin sulfate during the first minutes. The rapid release of 
gentamicin sulfate for both concentrations can be explained by the chemical bonds created 
between chitosan and gentamicin sulfate. The literature does not mention the possible 
connections but we can formulate a hypothesis. The most plausible hypothesis is that hydrogen 
bonds are formed between the OH groups of chitosan (figure 1) and gentamicin sulfate (figure 2) 
creating a “zipper effect”. Indeed, hydrogen bonds involve a hydrogen atom and an 
electronegative atom (such as oxygen). Hydrogen bonds have a low intensity (20 times weaker 
than the covalent bonds). This hypothesis could therefore justify and explain the rapid release of 
gentamicin sulfate from the first minutes of immersion of the scaffolds in PBS. 
4. Conclusions
Porous CH-BG scaffolds were developed for use in bone tissue engineering applications. The 
antibiotic gentamicin sulfate was entrapped into the scaffolds via the freeze-drying method to 
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confer them the drug release capability. The increase of specific surface area, average pore 
diameter and pore volume are observed when the content of chitosan is more important than that 
of bioactive glass 46S6. The in vitro assays of scaffolds in PBS show than the release of 
gentamicin sulfate increases with these three parameters. This drug was released in a controlled 
manner. The release rate, the relaxation time of scaffolds and the limit concentration were also 
dependent on the gentamicin sulfate concentration introduced in the beginning. Present CH-BG 
scaffolds, exhibiting a bioactive character in SBF and controlled release ability of an antibiotic, 
are proposed for bone tissue engineering. These biomaterials could be adapted at a clinical 
application and according to the advance of infection to treat. Scaffolds represent a new type of 
biomaterials in the field of therapeutic materials for the tissue engineering. 
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Caption Figures 
Figure 1: Chemical formula of chitosan  
Figure 2: Chemical formula of gentamicin sulfate  
Figure 3: Steps in the synthesis of scaffolds  
Figure 4: BET analysis of scaffolds 
Figure 5: SEM micrographs (x700) of scaffolds before soaking:  a 1CH-1BG, b 1CH-2BG, c
2CH-1BG and (x5000): d 1CH-1BG, e 1CH-2BG, f 2CH-1BG 
Figure 6: Diffractograms of scaffolds before and after immersion in SBF 
Figure 7:  FTIR spectra of scaffolds before and after immersion in SBF 
Figure 8: SEM micrographs (x5000) of scaffolds after 30 days of soaking in SBF: d 1CH-1BG, e
1CH-2BG, f 2CH-1BG 
Figure 9.a Si concentration after immersion at different times in SBF 
Figure 9.b Ca concentration after immersion at different times in SBF 
Figure 9.c P concentration after immersion at different times in SBF 
Figure 10.a Release of gentamicin after immersion in the PBS 
Figure 10.b Release of gentamicin after immersion in the PBS 
Highlights
• The chemical composition of scaffolds influences the release of gentamicin sulfate. 
• The concentration of gentamicin sulfate has an influence on the relaxation time of 
scaffolds. 
• An increasing concentration of gentamicin sulfate delays the return to a new equilibrium. 
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Scaffolds Content of chitosan (g) Content of bioactive glass (g)
2CH-1BG 3 1.5 
1CH-1BG 3 3 
1CH-2BG 3 6 
Table 1: Chemical composition of scaffolds 
Ions Na
+
K
+
Mg
2+
Ca
2+
Cl
-
HCO3
-
HPO4
2-
SO4
2-
SBF 142,0 5,0 1,5 2,5 147,8 4,2 1,0 0,5 
Plasma 142,0 5,0 1,5 2,5 103,0 27,0 1,0 0,5 
Table 2: Ionic concentrations of SBF and human blood plasma (mM) 
Scaffolds 2CH-1BG 1CH-1BG 1CH-2BG 
Specific Surface Area 
(m².g
-1
) 
7.90 ± 0.08 7.60 ± 0.08 6.90 ± 0.07 
Average Pore Diameter 
(nm) 
5.20 ± 0.03 3.60 ± 0.03 4.00 ± 0.03 
Pore Volume (mm
3
.g
-1
) 8.10 ± 0.08 7.4 ± 0.07 7.00 ± 0.07 
Table 3: Textural properties of the three kinds of scaffolds 
Material Wave number (cm
-1
) Group assignment References 
Chitosan 1900-1500 Amide I: C=O [31] 
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Chitosan 1650-1550, 1570-1515 N-H(I), N-H(II) [31] 
Chitosan 1154-896 COC (saccharide--1-4) [31] 
Chitosan 1300-1000 C-O (cyclic) [31] 
BG 1350-1080 P=O Stretch [32] 
BG 940-860 Si-O-Si Stretch [32] 
BG 890-800 C-O Stretch [32] 
BG 1175-710 Si-O-Si Tetrahedral [32] 
BG 560-550 P-O Bend [32] 
BG 540-415 Si-O-Si Bend [32] 
Table 4: Major vibration bands associated with chitosan and bioactive glass 
Scaffolds 1% 








	




−−×=
τ
t
CgC exp10
 C0 (mg/mL)  (minutes) Laws 
1CH :2BG 1.90 ± 0.01 29 








	




−−×=
29
exp190.1
t
gC
1CH :1BG 4.00 ± 0.01 30 








	




−−×=
30
exp100.4
t
gC
2CH :1BG 6.20 ± 0.01 28 








	




−−×=
28
exp120.6
t
gC
Table 5: Laws of kinetics for scaffolds with 1% of gentamicin 
Scaffolds 3% 








	




−−×=
τ
t
CgC exp10
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 C0 (mg/mL)  (minutes) Laws 
1CH :2BG 6.00 ± 0.01 38 








	




−−×=
38
exp100.6
t
gC
1CH :1BG 6.30 ± 0.01 38 








	




−−×=
38
exp130.6
t
gC
2CH :1BG 12.40 ± 0.01 38 








	




−−×=
38
exp140.12
t
gC
Table 6: Laws of kinetics for scaffolds with 3% of gentamicin 
